Triple-negative breast cancer (TNBC) is a highly aggressive subtype, characterized by absent expression of estrogen receptor (ER), progesterone receptor (PR) and epidermal growth factor receptor (HER2), which render TNBC lacking effective targets for drug intervention [3], with chemotherapy being the only accessible choice. This evidence concerns the gene PGR and triple-negative breast carcinoma.